secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002092
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools reports preliminary FY2023 rev $106M; merger closed Jan 5, combined cash >$550M
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue ~$28M and full year ~$106M for Standard BioTools.
- SomaLogic preliminary Q4 revenue ~$23M and full year ~$86M.
- Core revenue grew >10% YoY; instrument revenue grew >40% YoY.
- Merger with SomaLogic completed Jan 5, 2024; combined cash >$550M as of Dec 31, 2023.
- Company to report full Q4 and FY2023 results in early March with 2024 outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/tm2333984d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer